Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 21, 2015

Key Late-breaking Trials to Watch at ACC.15

The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in March. Here are my top picks for cardiovascular device technology I am looking forward to hearing data on: 

1. Perhaps the key trial at ACC will be data from the large BEST study, which compares the Xience V drug-eluting stent (DES) to coronary bypass grft (CABG) surgery in patients with multivessel disease. It is a follow up to the SYNTAX trial, which fell short in showing the Taxus DES (at the time the top-performing stent) had long-term durability compared to CABG. However, Abbott's Xience second-generation DES beat out Taxus in the SPRIRT IV trial a couple years ago. Intervascular imaging and FFR today also see more expanded use, which combined with an improved stent platform, is expected to tip the scale in favor of stenting. 

2. More data will be presented, likely further supporting the use of transcatheter aortic valve replacement (TAVR). This includes long-term outcomes from the Edwards Sapien and Medtronic Corevalve trials, and first experience with use of a TAVR embolic protection system. The most important of the trial presentations might be data from an all-comers trial of TAVR verses surgery. This data could help open the flood gates for TAVR as a standard therapy to replace open heart procedures.
 
3. Use of CT angiography to evaluate patients presenting with chest pain to reduce costs. There a a few CTA trials being presented, which I suspect will add more evidence that CTA can be used as a primary rule-out test to help eliminate series blood testing, nuclear scans, stress tests and diagnostic angiograms.
 
4. Denervation to treat pulmonary hypertension. Renal denervation trials have had very mixed results, but experts still say the denervation may hold promise for other therapeutic areas such as this one.
 
5. Initial experience and outcomes with the MitraClip mital valve leaflet repair system. I believe this is just the beginning of a whole new segment of interventional mitral valve repair therapies that will eventually replace open heart mitral procedures.
 
6. There are two trials comparing transradial access, which is a growing trend in the United States to help lower access site complications. One will compare transradial to transfemoral access sites, and another radial verses ulnar access. 
 
See the complete list of late breaking trials, presentation locations and times. 

Below is a preview of some technologies being shown on the expo floor.

 

Related Content

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients.

News | Heart Failure | June 15, 2021
June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

News | Heart Failure | June 07, 2021
June 7, 2021 – Cardiologists at Hen...
RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart  heart and atrial fibrillation. #ACC21 #ACC2021

RAFT-AF study showed the type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. Getty Images

News | Heart Failure | May 19, 2021
May 19, 2021 — Among patients with both ...
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients.

News | Heart Failure | May 18, 2021
May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a gre
The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021

The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor.

News | Heart Failure | May 15, 2021
May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the ra
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 

Getty Images

News | Heart Failure | May 11, 2021
May 11, 2021 — Patients hospitalized with COVID-1...
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

News | Heart Failure | April 26, 2021
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States.
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating
Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

News | Heart Failure | March 03, 2021
March 3, 2021 — Impulse Dynamics recently announced that...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — P...